spermatogenesis continues from puberty up to old age, there is more opportunity for preconceptional mutant gene accumulation in men than in women. Benzo [a]pyrene is a potent carcinogen in cigarette smoke, its reactive metabolite induces DNA adducts, which can cause mutations. These DNA adducts were found in spermatozoa of a smoker and his embryo.
Passive child exposure to tobacco smoke had a higher risk than the one reported elsewhere. As shown by others, 8 when several subjects smoked in front of the child, the risk was evident; large amounts of carcinogenic, volatile nitrosamines and aromatic amines are present in the inhaled smoke stream, although the concentration of these compounds is about two orders of magnitude lower than in active cigarette smokers, suggesting that some risk genotypes are particularly susceptible to low doses of carcinogens. It has been claimed that smoke exposure is prevalent among Hispanics and Afro-Americans. In these groups, the population of children is larger than in Caucasians and they are more vulnerable to the toxic effects of environmental tobacco smoke. 8 Other possible mechanisms may include stimulation of angiogenesis and tumor growth promotion by nicotine. Angiogenesis has indeed been associated with AL.
In conclusion, childhood leukemia is a heterogeneous disease with individual subtypes in which the response to chemotherapy and its causes may be different. It is possible that acute leukemia share etiologies, as shown for lymphoma or thyroid cancer in children. The results of this study are encouraging, but the sample size should be increased and other studies in different populations should be performed to confirm these data. Research of the risk factors leading to leukemia is relevant to identify strategies to develop protective policies and interventions.
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This study was supported by Grant G30670-M of the Consejo Nacional de Ciencia y Tecnología (CONACyT) and FP-00038/218/ 415/458/459 of the Instituto Mexicano del Seguro Social. We are also indebted to the Instituto de Diagnó stico y Referencia Epidemioló gicos who partly supported the study. We are very grateful to Dod Stewart for revising the manuscript; to Carmen Alaez, Miriam Vázquez and Gabriela de la Rosa for their very helpful discussions. We also thank Mtra Sylvia García of the John Langdon Down Institute and to Dra Susana Ramírez Robles, Lic Ma de los Angeles Rojas Ramírez and Dr Pedro González Vivanco of the Integral Care for Persons with Down's Syndrome (CTDUCA) for providing the DS children included in this study. [1] [2] [3] [4] [5] [6] [7] In initial reports, patients expressing the CBFb-MYH11 chimeric gene in the absence of chromosome 16 aberrations were reported to account for up to 43% of all molecularly positive patients. [2] [3] [4] Other studies have reported a much lower incidence of such discordance between cytogenetic and molecular analyses. 1, [5] [6] [7] These discrepancies may be a consequence of the difficulty in detecting the inv(16) cytogenetically. 8 In all these reports, the expression of CBFb-MYH11 fusion transcripts in the presence of a normal karyotype without chromosome 16 abnormalities and other cytogenetic aberrations was rare. In the studies providing information on the number of patients with a normal karyotype, the incidence of molecularly positive disease was 1.5% (one of 65), 2 1.1% (one of 87), 7 and 0.8% (one of 124)
1 . In the latter study, the single patient initially reported as having a normal karyotype was found to have inv(16) on re-examination. 1 In the study of 412 patients by Rowe et al., /l. Other significant abnormal laboratory findings included a serum LDH of 1641 m/l and a pO 2 of 62 mmHg. On examination he was dyspneic and tachypneic but afebrile, with stable hemodynamic indices. He also had clinically evident bilateral pleural effusions and generalized abdominal discomfort with no rebound tenderness or rigidity. Bone marrow examination showed extensive replacement with leukemic cells, which were positive for surface markers CD13, CD33, HLA-DR, CD14, CD15, CD11C, CD11b, and MPO, supporting the diagnosis of AML M4. A relative increase in eosinophilic precursors was also noted. Cytogenetic analysis of the bone marrow including FISH analysis of CBFb showed a normal male karyotype and the absence of chromosome 16 abnormalities ( Figure 1a ). Molecular analysis was positive for the CBFb-MYH11 fusion transcripts by RT-PCR. These initial diagnostic studies were performed by the Cancer and Leukemia Group B (CALGB), as well as by Genzyme Genetics laboratories. He was initiated on leukapheresis, supportive care and chemotherapy with cytosine arabinoside (ara-C), daunorubicin, and etoposide in addition to the multidrug-resistance (MDR) modulating drug PSC833 on a cooperative group clinical trial. He responded satisfactorily and achieved a complete remission (CR) with the first induction course. The remission was consolidated by three cycles of high-dose ara-C and he remained in CR until 10 months later when his leukemia relapsed. Repeat analyses for CBFb-MYH11 fusion were performed by cytogenetic, FISH, and RT-PCR methods at our institution (Figures 1b, c and 2, respectively). A second CR was achieved using salvage chemotherapy, and he subsequently underwent an unrelated donor transplant. At the time of this report, he had fully engrafted without any significant complications at day 80.
The initial cytogenetic analyses at Genzyme Genetics and CALGB laboratories showed a normal male karyotype without evidence of inversion or translocation 16 ( Figure 1a) ; studies at 1 and 6 months (in CR) after initial presentation were also normal. Cytogenetic analysis at first relapse, performed by Genzyme Genetics, 10 months after initial presentation, still failed to detect inv(16) or t(16:16), but at this point 20% of the metaphases did have a deletion of the long arm of chromosome 7 [del(7)(q31q36)] as the sole abnormality. After a second CR with salvage chemotherapy, the karyotype was again normal.
Cytogenetic analysis at second relapse performed at UIC still did not reveal inversion 16, but detected the del(7) in 45% of the cells (Figure 1b) . FISH analysis of interphase and metaphase cells using the Vysis dual color, break apart probe for CBFb failed to detect any rearrangement, either in interphase cells or in metaphase cells evidencing the del(7) (Figure 1c ).
Molecular analysis of patient RNA at relapse by one-step RT-PCR (Qiagen, Inc., Valencia, CA, USA) followed by nested PCR amplification showed a 268 bp product (Figure 2 ), which comigrated with the product from the positive control cell line, ME-1f2. The first-round primers were sense: 5 0 GCAGGGAGAACAG CGACAAACA3 0 , antisense: 5 0 TCTGGAGGCACGGGCATC3 0 . Nested primers were sense: 5 0 ATGGGCTGTCTGGAGTTTGAT3 0 , antisense: 5 0 GCGCCTGCATGTTGACTT3 0 . ME-1f2, which is a subline of ME-1, expresses CBFb-MYH11 fusion transcripts (personal communications with Dr Sakai, Japan). In addition, the nested PCR product was sub-cloned into the pCRII TOPO vector and sequenced to further confirm product identity and to determine the breakpoints in the CBFb and MYH11 genes. Sequence analysis showed that the breakpoint was at nucleotide position 495 in CBFb (Genbank sequence AF294326, gi: 9885832) and at nucleotide position 1921 in MYH11 (Genbank sequence D10667, gi: 532875). Thus, our patient's leukemic cells expressed the typical Type A fusion transcript. ME-1f2 cells appeared to show two additional faint bands upon higher exposure of the gel. These bands probably represent alternatively spliced products. Such alternatively spliced products have been previously reported from clinical samples. 9 The focus of this report was to determine whether the patient expressed inversion 16 fusion transcripts and hence we concentrated on the 268 bp product, which was the predominant product from both the patient and ME-1f2 cells. Furthermore, we confirmed the identity of the fusion transcript by sequence analysis. ME-1f2 cells were solely used to serve as a positive control for the Type A fusion transcript in our assay and it is quite possible that they express fusion transcripts other than Type A.
Acute myeloid leukemias that express fusion transcripts containing CBF sequences are associated with a more favorable prognosis, particularly if treated with intensive postremission therapy including high-dose cytarabine. Therefore, accurate identification of these patients at diagnosis will allow the benefit of such therapy, while sparing them the more aggressive and potentially more toxic therapeutic interventions such as allogeneic transplantation. Inversion 16 and its variant translocation are subtle changes that can be relatively difficult to identify by standard cytogenetics. 1, 8 Although the breakpoints in the CBFb and MYH11 genes are variable and more than 10 different transcripts have been reported, the majority of patients (85%) have the type A transcript. Several studies have examined the frequency of patients with the CBFb-MYH11 transcripts, who do not have detectable chromosome 16 aberrations. Although initial reports suggested a high incidence of such patients, recent reports have suggested a far lower frequency of such discordance. In particular, the presence of the fusion transcript in patients with a completely normal karyotype by cytogenetic and/or FISH analysis is exceedingly rare, with only 7 reported patients including the one reported here.
Three independent laboratories failed to detect a chromosome 16 abnormality in our patient. Therefore, we believe that the amount of genetic material involved is small in size and below the resolution of standard cytogenetic or FISH analysis with the probes commonly used for clinical detection of this rearrangement. Moreover, conventional cytogenetic analysis cannot detect cryptic deletions of sequences centromeric to the p-arm breakpoint described in a subset of patients. 10 Investigation of this possibility would require the use of specially designed FISH probes or special FISH techniques not normally used in routine practice. 10 Our report further emphasizes the importance of routine molecular analysis in addition to cytogenetic and FISH studies to detect CBFb-MYH11 fusion transcripts in cases of AML suspected to harbor CBF rearrangements. Furthermore, molecular analysis can provide rapid results to aid in the decision-making process and identify breakpoints that may have potential prognostic significance. Molecular analysis can also be used in monitoring remission in these patients. 11 Although several investigators have argued that molecular testing may not be justified in patients with a successful cytogenetic study and a normal karyotype (particularly if this is confirmed by FISH), 1 our case illustrates the existence of rare patients with a cryptic molecular abnormality. Other cytogenetic abnormalities such as +22 have been commonly associated with inv(16)/t(16;16) and a search for cryptic transcripts in patients harboring them is also important. 1, 8 Patients with abnormalities involving CBF have the highest CR rates, the longest CR duration, and overall survival times. Our patient was treated with an anthracycline-containing regimen and received three cycles of consolidation with high-dose cytarabine, but had a remission of short duration confirming that other, as yet unknown, molecular events are of prognostic significance in CBF leukemias. At relapse, a deletion of the long arm of chromosome 7 appeared. The significance of such secondary cytogenetic changes and their role in causing relapse and disease progression remain undetermined. However, these secondary molecular abnormalities may contribute to disease progression, as hypothesized in the multihit theory of leukemogenesis.
The expert technical assistance of Andrew Miner is gratefully acknowledged. We also thank Drs K Richkind and P Rushton of Genzyme Genetics for their kind contribution of Figure 1a . F Ravandi and SS Kadkol contributed equally to this work. 2 can be differentiated into functionally active DC capable of inducing antileukemia T-cell responses. 3, 4 We were interested in the utilization of such an immunotherapeutic approach for patients with juvenile myelomonocytic leukemia (JMML), a rare condition with poor prognosis. This approach is attractive because allogeneic BMT is considered necessary for cure, and the graft-versus-leukemia (GVL) effect is critically important. 5, 6 We initially assessed whether immature DC could be generated in vitro from plastic adherent peripheral blood mononuclear cells (PBMC) from three JMML patients (JMML-1, -2, -3). After 6 days of culture with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) in the presence of 10% fetal calf serum, cells from normal donors and all three JMML patients demonstrated a typical immature monocyte-derived DC (MoDC) surface phenotype. This was inferred from their high expression levels of the myeloid marker CD11c, intermediate levels of the MHC class II molecule HLA-DR and the costimulatory molecule CD86 (B7-2), and undetectable levels of the dendritic activation marker CD83 and the monocytic marker CD14 (Figure 1) . Typically, 10 ml of peripheral blood from JMML patients yielded about 5 Â 10 7 adherent cells and the final yield of viable MoDC was between 25 and 50% of this starting population. The cells generated from normal donors and JMML patients formed nonadherent clusters and possessed short cytoplasmic projections, characteristic of immature DC morphology. 7 Immature DC are specialized at capturing and processing antigens; however, optimal presentation of potential leukemiaspecific antigens to T lymphocytes requires that the DC are in an activated, mature state. 7 Therefore, we next attempted to activate the in vitro cultured immature DC with lipopolysaccharide (LPS). Immature DC populations generated from normal, JMML-1, and JMML-2 PBMC upregulated HLA-DR, CD83 and CD86 expression following 24-h exposure to LPS, acquiring a mature dendritic phenotype (Figure 1 ). These mature DC therefore expressed the necessary cell surface molecules required for efficient antigen presentation and costimulation. However, the DC cultured from JMML-3 PBMC failed to upregulate HLA-DR and CD83 following addition of LPS (data not shown).
The leukemic cells in two of the patients (JMML-2 and -3) exhibited monosomy 7, a commonly observed chromosomal abnormality of this disease. We were able to use this as a marker of malignant origin, and interphase fluorescence in situ hybridization (FISH) analysis revealed that the vast majority of CD86 + -purifed mature DC generated from these patients displayed monosomy 7 (98% of JMML-2 DC and 91% of JMML-3 DC). In contrast, DC cultured from PBMC from a normal donor all possessed two copies of chromosome 7. This finding confirmed that virtually all the DC cultured in vitro from these JMML patients were of leukemic origin.
Several experiments were performed to investigate the functional activity of these leukemic DC. Limited sample sizes prevented us from examining the functional activity of DC cultured from all three JMML patients in each assay. To examine further the ability of in vitro cultured DC to provide the costimulatory signal required to activate naïve T cells, we measured DC production of IL-12 by ELISA (Becton Dickinson, San Diego, CA, USA). Secretion of IL-12 by mature DC is required for T-cell activation, and is associated with a Th-1 response. Consistent with published data, immature DC generated in vitro from normal donor and JMML-2 PBMC did not secrete IL-12 (o7.5 pg/150 000 cells). However, LPS-matured MoDC from a normal donor and LPS-matured DC from JMML-2 produced large amounts of IL-12 (210 pg/150 000 cells and 320 pg/ 150 000 cells, respectively). These results provide additional evidence for the stimulatory phenotype of mature DC generated from JMML-2 PBMC. In contrast, incubation of immature DC cultured from JMML-3 PBMC with LPS for 24 h resulted in the secretion of minimal amounts of IL-12 (15 pg/150 000 cells), significantly less than that observed in normal mature MoDC (Po0.05, Student's t-test). This abnormal secretion of IL-12 by JMML-3 DC following incubation with LPS is consistent with the flow cytometric data, demonstrating that the DC cultured from this patient were resistant to activation with LPS. The variability in the phenotypes of the DC generated from the three JMML patients might reflect the heterogeneity of this disorder. Received 
